MUC1 expression in Sjogren's syndrome, KCS, and control subjects.
OBJECTIVE
To quantify and compare human mucin 1 (MUC1) protein and mRNA expression in tears and conjunctival epithelial cells collected from Sjogren's syndrome (SS), non-Sjogren's keratoconjunctivitus sicca (KCS) and non-dry eyed (NDE) control subjects.


METHODS
Seventy-six subjects were recruited for this study: 25 SS (confirmed via American-European Consensus Criteria 2002), 25 KCS (confirmed by symptoms and Schirmer scores < or = 10 mm) and 26 NDE. Tears were collected using an eye-wash technique. Impression cytology was used to gather protein and mRNA from conjunctival epithelial cells. Soluble and membrane bound MUC1 were quantified via western blotting and MUC1 mRNA was quantified by real time qPCR.


RESULTS
The SS group demonstrated significantly higher concentrations of soluble MUC1 (0.12 +/- 0.11 [SS]; 0.013 +/- 0.02 [KCS; p=0.001]; 0.0023 +/- 0.0024 [NDE; p<0.001]) and MUC1 mRNA (3.18 +/- 1.44 [SS]; 1.79 +/- 1.18 [KCS; p<0.05]; 1.60 +/- 0.74 [NDE; p<0.05]) compared to both KCS and NDE groups. Soluble MUC1 expression was also higher in the KCS group compared to the NDE group (p=0.02), where as MUC1 mRNA expression was similar in both KCS and NDE groups. Membrane bound MUC1 expression differed only between the SS and NDE groups (0.005 +/- -0.003 [SS]; 0.003 +/- 0.002 [NDE; p=0.002]).


CONCLUSIONS
These results demonstrate that SS subjects express greater quantities of MUC1 protein and mRNA compared to both KCS and control subjects. Increased soluble MUC1 expression was also found in KCS subjects compared to controls. Membrane bound MUC1 was present in higher concentration in SS versus NDE only. These significant changes in MUC1 expression may represent compensatory or protective responses to chronic insult to the ocular surface.
Caffery
Barbary
B
Center for Contact Lens Research, School of Optometry, University of Waterloo, Ontario, Canada. barbaracafferyeyes@yahoo.ca
Heynen
Miriam L
ML
Joyce
Elizabeth
E
Jones
Lyndon
L
Ritter
Robert
R
Senchyna
Michelle
M
D015153:Blotting, Western; D016022:Case-Control Studies; D003228:Conjunctiva / Q000378:metabolism / Q000473:pathology; D003710:Demography; D004847:Epithelial Cells / Q000378:metabolism / Q000473:pathology; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D007638:Keratoconjunctivitis Sicca / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D018396:Mucin-1 / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012044:Regression Analysis; D012859:Sjogren's Syndrome / Q000235:genetics / Q000378:metabolism*; D012995:Solubility; D013666:Tears / Q000378:metabolism
D018396:Mucin-1; D012333:RNA, Messenger
Exp Eye Res. 2010 Mar;90(3):444-51
20036239
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4509-18
17898272
Adv Exp Med Biol. 1994;350:239-47
8030483
Trans Ophthalmol Soc U K (1962). 1985;104 ( Pt 4):381-9
3898473
J Clin Invest. 2007 Aug;117(8):2313-24
17641781
Cancer Res. 1987 Oct 15;47(20):5476-82
2443241
Ocul Surf. 2007 Apr;5(2):75-92
17508116
J Biol Chem. 2009 Aug 21;284(34):23037-45
19556244
J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):339-53
11547902
Invest Ophthalmol Vis Sci. 2000 May;41(6):1316-26
10798646
Invest Ophthalmol Vis Sci. 1995 Aug;36(9):1818-27
7635656
Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 2):S44-8
10556169
Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2602-9
9856770
Trends Cell Biol. 2006 Sep;16(9):467-76
16904320
Curr Opin Allergy Clin Immunol. 2008 Oct;8(5):477-83
18769205
J Biol Chem. 2001 May 25;276(21):18327-36
11278439
Annu Rev Physiol. 1995;57:607-34
7778880
Cornea. 1988;7(1):71-81
3280239
Invest Ophthalmol Vis Sci. 2004 Jan;45(1):114-22
14691162
Cornea. 2001 Nov;20(8):873-7
11685069
Cornea. 2000 Sep;19(5):644-9
11009316
Invest Ophthalmol Vis Sci. 2010 May;51(5):2381-7
20107179
Ophthalmology. 1997 Feb;104(2):223-35
9052626
Exp Eye Res. 2007 May;84(5):939-50
17399701
Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2487-95
12766047
Biochem Biophys Res Commun. 2002 Mar 1;291(3):466-75
11855812
Invest Ophthalmol Vis Sci. 1996 Jul;37(8):1684-92
8675412
Annu Rev Physiol. 2008;70:431-57
17850209
Nat Struct Mol Biol. 2006 Jan;13(1):71-6
16369486
Infect Immun. 1994 May;62(5):1799-804
8168942
Exp Eye Res. 2004 Mar;78(3):379-88
15106916
Cornea. 2005 Nov;24(8 Suppl):S18-S23
16227818
Int Arch Allergy Appl Immunol. 1989;90(3):307-9
2556352
Cornea. 2006 Feb;25(2):176-81
16371777
J Biol Chem. 2001 Jul 20;276(29):27371-5
11369781
J Biol Chem. 2004 Jan 16;279(3):1968-79
14565953
Invest Ophthalmol Vis Sci. 2003 Jan;44(1):86-92
12506059
Cancer Res. 1999 Aug 15;59(16):4083-9
10463611
Cancer Res. 1992 Apr 1;52(7):1954-60
1372533
Invest Ophthalmol Vis Sci. 2002 Apr;43(4):1004-11
11923240
Cornea. 1996 May;15(3):229-34
8713923
Optom Vis Sci. 1989 Mar;66(3):175-8
2717147
Proc Natl Acad Sci U S A. 1987 Sep;84(17):6060-4
2888110
Exp Eye Res. 1973 May 10;15(5):515-25
4712544
Ann Rheum Dis. 2002 Jun;61(6):554-8
12006334
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):113-9
16384952
Eur J Biochem. 2002 Jun;269(11):2755-63
12047385
Invest Ophthalmol Vis Sci. 2000 Mar;41(3):703-8
10711684
J Clin Invest. 1983 Jul;72(1):122-7
6308043
Exp Eye Res. 2010 Jun;90(6):655-63
20223235
Am Rev Respir Dis. 1985 Jun;131(6):917-22
3923884
Mol Vis. 2008;14:2547-55
19122828
Exp Eye Res. 2006 Sep;83(3):493-501
16631167